GCH1, Polyclonal Antibody

GCH1; GTP cyclohydrolase 1 (dopa-responsive dystonia); DYT5; GCH; GTP-CH-1; GTPCH1; GTP cyclohydrolase 1; guanosine 5'-triphosphate cyclohydrolase I; GCH1 antibody; GTP cyclohydrolase 1 (dopa-responsive dystonia) antibody; DYT5 antibody; GCH antibody; GTP-CH-1 antibody; GTPCH1 antibody; GTP cyclohydrolase 1 antibody; guanosine 5\1-triphosphate cyclohydrolase I antibody

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Goat

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul (lot specific)

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Manufactured in an ISO 9001:2008 Certified Laboratory.

Small volumes of anti-GCH1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Peptide ELISA (EIA), Western Blot (WB)

Peptide ELISA: Antibody detection limit dilution 1: 16000.
Western Blot: Approx.37kDa band observed in Human Tonsil, Lymph Node and Thymus lysates. Customer's experiments gave identical results in lysates of cell line HUVEC with antibodies raised against different parts of the same protein. (calculated MW of 27.9kDa according to NP_000152.1). Recommended concentration: 0.5-1.5ug/ml.

(0.5ug/ml) staining of Human Tonsil lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

25,775 Da

GTP cyclohydrolase 1

GTP cyclohydrolase 1

GTP cyclohydrolase 1

DYT5; GCH; GTP-CH-I  [Similar Products]

GCH1_HUMAN

This gene encodes a member of the GTP cyclohydrolase family. The encoded protein is the first and rate-limiting enzyme in tetrahydrobiopterin (BH4) biosynthesis, catalyzing the conversion of GTP into 7,8-dihydroneopterin triphosphate. BH4 is an essential cofactor required by aromatic amino acid hydroxylases as well as nitric oxide synthases. Mutations in this gene are associated with malignant hyperphenylalaninemia and dopa-responsive dystonia. Several alternatively spliced transcript variants encoding different isoforms have been described; however, not all variants give rise to a functional enzyme. [provided by RefSeq, Jul 2008]

GCH1: Positively regulates nitric oxide synthesis in umbilical vein endothelial cells (HUVECs). May be involved in dopamine synthesis. May modify pain sensitivity and persistence. Isoform GCH-1 is the functional enzyme, the potential function of the enzymatically inactive isoforms remains unknown. Defects in GCH1 are the cause of GTP cyclohydrolase 1 deficiency (GCH1D); also known as atypical severe phenylketonuria due to GTP cyclohydrolase I deficiency;. GCH1D is one of the causes of malignant hyperphenylalaninemia due to tetrahydrobiopterin deficiency. It is also responsible for defective neurotransmission due to depletion of the neurotransmitters dopamine and serotonin. The principal symptoms include: psychomotor retardation, tonicity disorders, convulsions, drowsiness, irritability, abnormal movements, hyperthermia, hypersalivation, and difficulty swallowing. Some patients may present a phenotype of intermediate severity between severe hyperphenylalaninemia and mild dystonia type 5 (dystonia- parkinsonism with diurnal fluctuation). In this intermediate phenotype, there is marked motor delay, but no mental retardation and only minimal, if any, hyperphenylalaninemia. Defects in GCH1 are the cause of dystonia type 5 (DYT5); also known as progressive dystonia with diurnal fluctuation, autosomal dominant Segawa syndrome or dystonia- parkinsonism with diurnal fluctuation. DYT5 is a DOPA-responsive dystonia. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT5 typically presents in childhood with walking problems due to dystonia of the lower limbs and worsening of the dystonia towards the evening. It is characterized by postural and motor disturbances showing marked diurnal fluctuation. Torsion of the trunk is unusual. Symptoms are alleviated after sleep and aggravated by fatigue and excercise. There is a favorable response to L-DOPA without side effects. Belongs to the GTP cyclohydrolase I family. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Cofactor and Vitamin Metabolism - folate biosynthesis; EC 3.5.4.16; Hydrolase

Chromosomal Location of Human Ortholog: 14q22.1-q22.2

Cellular Component: cytoplasm; cytoplasmic vesicle; cytosol; nuclear membrane; nucleoplasm; nucleus; protein complex

Molecular Function: GTP binding; GTP cyclohydrolase I activity; mitogen-activated protein kinase binding; protein binding; protein homodimerization activity; zinc ion binding

Biological Process: dopamine biosynthetic process; neuromuscular process controlling posture; positive regulation of nitric-oxide synthase activity; protein homooligomerization; pteridine and derivative biosynthetic process; regulation of blood pressure; regulation of nitric-oxide synthase activity; response to lipopolysaccharide; response to pain; tetrahydrobiopterin biosynthetic process

Disease: Dystonia, Dopa-responsive; Hyperphenylalaninemia, Bh4-deficient, B

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.